CMP Scientific Corp. has signed a global co-marketing agreement with Agilent Technologies to provide an integrated capillary electrophoresis–mass spectrometry (CE-MS) solution to life science and pharmaceutical industry.

CMP and Agilent will work together to implement new applications for the CE-MS system, which is a sensitive, alternative method to liquid chromatography-mass spectrometry (LC-MS) in mapping biological components.

One of CMP’s major products, EMASS-II CE-MS ion source integrates seamlessly with the Agilent’s MS instruments to identify therapeutic monoclonal antibody (mAb) charge variants, and to analyze other diverse biological molecules.

CMP first introduced the EMASS-II CE-MS, which utilizes an electrokinetically pumped nanospray sheath liquid interface to provide reliable and robust performance, in 2015. Leading biopharmaceutical companies now routinely use the EMASS-II CE-MS ion source in high sensitivity applications ranging from mAb intact mass analysis, charge variant analysis, CE-SDS impurity analysis, subunit analysis, peptide mapping analysis, biosimilar comparisons to preclinical biotransformation studies. This interface has also been globally employed for metabolite analysis, nucleic acid analysis and polysaccharide analysis.